Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Depreciation & Amortization (CF): 2014-2025

Historic Depreciation & Amortization (CF) for vTv Therapeutics (VTVT) over the last 11 years, with Sep 2025 value amounting to $2,000.

  • vTv Therapeutics' Depreciation & Amortization (CF) fell 90.91% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $47,000, marking a year-over-year decrease of 53.00%. This contributed to the annual value of $100,000 for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Depreciation & Amortization (CF) is $2,000, which was down 33.33% from $3,000 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Depreciation & Amortization (CF) registered a high of $33,000 during Q4 2021, and its lowest value of $2,000 during Q3 2025.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $22,000 (2024), whereas its average is $19,455.
  • As far as peak fluctuations go, vTv Therapeutics' Depreciation & Amortization (CF) climbed by 17.86% in 2021, and later plummeted by 90.91% in 2025.
  • Quarterly analysis of 5 years shows vTv Therapeutics' Depreciation & Amortization (CF) stood at $33,000 in 2021, then declined by 6.06% to $31,000 in 2022, then increased by 6.45% to $33,000 in 2023, then remained steady at $33,000 in 2024, then tumbled by 90.91% to $2,000 in 2025.
  • Its Depreciation & Amortization (CF) was $2,000 in Q3 2025, compared to $3,000 in Q2 2025 and $9,000 in Q1 2025.